Anteris Technologies Reaches Clinical Milestone: 100 patients treated with DurAVR THV MINNEAPOLIS, United States and BRISBANE, Australia 31 March 2025: Anteris Technologies Global Corp. ( Anteris or the Company ) (NASDAQ

Anteris Technologies Reaches Clinical Milestone: 100 patients treated with DurAVR THV

MINNEAPOLIS, United States and BRISBANE, Australia 31 March 2025: Anteris Technologies Global Corp. (Anteris or the Company)

(NASDAQ: AVR, ASX: AVR) a global structural heart company committed to designing, developing, and commercializing cutting-edge medical devices, announces a significant milestone in our mission to restore heart valve patients to healthy function.

Our first in class, biomimetic DurAVR Transcatheter Heart Valve (THV) has now been used to treat over 100 patients worldwide, marking a major achievement in our goal to revolutionize cardiac care in patients affected by severe aortic

Anteris Chief Medical Officer, Chris Meduri, M.D., commented: "We are incredibly proud to have reached this milestone, which represents years of dedication, research,

and importantly collaboration with expert physicians in the field. The excellent hemodynamic performance we are seeing is noteworthy in that it shows that DurAVR has the potential to restore natural heart valve function and thereby

redefine what success looks like in the treatment of aortic stenosis."

Dr. Michael Reardon, Allison Family Distinguished Chair of Cardiovascular Research and Professor of Cardiothoracic Surgery at the Houston Methodist Hospital and Study

Chair of the DurAVR THV Pivotal Trial said, "We are building on a strong foundation of clinical evidence, and we remain committed to rigorous scientific evaluation as we progress toward the all-risk, head-to-head, DurAVR registration

Vice Chairman and CEO, Wayne Paterson added, "This is a clinical milestone for the company and its investors. Not only have we crossed the threshold of having treated

over 100 patients, but we have achieved results that are clinically relevant and significantly differentiated to current therapies. DurAVR is the first new class of product in this space in many years and the current results across often

complex patients confirms the value of the product for physicians and patients as we move into our registration trial this year."

The Company remains on track to commence the DurAVR THV Pivotal Trial in the third quarter of 2025, pending U.S. Food and Drug Administration ("FDA")

*A bicuspid aortic valve (BAV) is a congenital heart condition where the aortic valve, which regulates blood flow from the heart to the aorta, has only two leaflets (or

flaps) instead of the normal three.

Anteris Technologies Global Corp. (NASDAQ: AVR, ASX: AVR) is a global structural heart company committed to designing, developing, and commercializing cutting-edge

medical devices to restore healthy heart function. Founded in Australia, with a significant presence in Minneapolis, USA, Anteris is a science-driven company with an experienced team of multidisciplinary professionals delivering restorative solutions

to structural heart disease patients.

Anteris' lead product, the DurAVR Transcatheter Heart Valve (THV), was designed in

partnership with the world's leading interventional cardiologists and cardiac surgeons to treat aortic stenosis - a potentially life-threatening condition resulting from the narrowing of the aortic

valve. The balloon-expandable DurAVR THV is the first biomimetic valve, which is shaped to mimic the performance of a healthy human aortic valve and aims to replicate normal aortic blood flow. DurAVR THV is made using a

single piece of molded ADAPT tissue, Anteris' patented anti-calcification tissue technology. ADAPT tissue, which is FDA-cleared, has been used clinically for over 10 years and distributed for use in over 55,000 patients

worldwide. The DurAVR THV System is comprised of the DurAVR valve, the ADAPT tissue, and the balloon-expandable ComASUR Delivery System.

Forward-Looking Statements

This announcement contains forward-looking statements. Forward-looking statements include all statements that are not historical facts. Forward-looking statements

generally are identified by the words "believe," "project," "expect," "anticipate," "estimate," "intend," "budget," "target," "aim," "strategy," "plan," "guidance," "outlook," "intend," "may," "should," "could," "will," "would," "will be," "will

continue," "will likely result" and similar expressions, although not all forward-looking statements contain these identifying words. These forward-looking statements are subject to a number of risks, uncertainties, and assumptions, including those

described under "Risk Factors" in Anteris' Annual Report on Form 10-K for the fiscal period ended December 31, 2024 that was filed with the SEC and ASX. Readers are cautioned not to put undue reliance on forward-looking statements, and except as

required by law, neither ATL or Anteris assume any obligation to update any of these forward-looking statements to conform these statements to actual results or revised expectations.

Authorisation and Additional information

This announcement was authorised for release on the ASX by the Board of Directors.

For more information: